Without treatment, AIDS is almost universally fatal, typically killing within two to three years of diagnosis. But with modern antiretroviral therapy, HIV has shifted from a death sentence to a manageable chronic condition. A 40-year-old who starts treatment early and responds well can now expect to live into their late 70s, only a few years less than someone without the virus.
The gap between those two realities is enormous, and it depends almost entirely on access to treatment and how early it begins. In 2024, about 630,000 people worldwide still died from AIDS-related illnesses, down from a peak of 2.1 million in 2004. That decline tells the story of a disease whose deadliness is now largely a function of circumstance.
What Happens Without Treatment
HIV attacks the immune system’s coordinator cells, gradually destroying the body’s ability to fight off infections. Left untreated, the time between initial HIV infection and an AIDS diagnosis is usually 10 to 15 years, according to the World Health Organization. During that period, the immune system slowly weakens. Once a person crosses the threshold into AIDS, their immune defenses are so depleted that ordinary infections become life-threatening.
Tuberculosis is the leading killer of people with AIDS globally. Other common fatal infections include a type of pneumonia caused by a fungus that healthy immune systems easily suppress, as well as severe bacterial pneumonia. Certain cancers that the immune system normally keeps in check, like Kaposi sarcoma and aggressive lymphomas, also become far more common. Without any intervention, most people with AIDS die within two to three years, and many die much sooner if they develop one of these serious complications.
How Treatment Changed the Equation
Antiretroviral therapy works by suppressing HIV to undetectable levels in the blood, allowing the immune system to rebuild. The improvement in survival has been dramatic. A large collaborative study published in The Lancet found that a 40-year-old man with HIV who started treatment after 2015 and achieved a strong immune recovery could expect roughly 39 more years of life. For women in the same situation, the estimate was about 42 more years. Those numbers put life expectancy within just a few years of the general population.
The key factor is the strength of immune recovery, measured by the count of a specific type of immune cell. When that count climbs above a healthy threshold, the risk of death drops sharply and begins to resemble that of people without HIV. Below that threshold, mortality risk rises steeply. Research from a 10-year cohort study found that the critical dividing line sits at roughly 350 of these immune cells per microliter of blood. Above that level, additional gains in survival flatten out. Below it, the risk of dying climbs significantly.
Why Early Diagnosis Matters So Much
People diagnosed late, after their immune system has already been severely damaged, face a much harder road. Their mortality risk in the first two years of treatment is substantially higher than for people who start treatment early. One prospective study found that late presenters whose immune counts remained below 200 cells per microliter two years after starting therapy had roughly 4.6 times the mortality risk of people diagnosed earlier.
The encouraging finding, though, is that late diagnosis is not permanently disqualifying. People who start treatment late but manage to rebuild their immune system to healthy levels within two years achieve survival rates comparable to those who were diagnosed on time. The immune system has a remarkable capacity to recover if given the chance, but those first two years carry real danger for people who begin treatment in an already weakened state.
Children Face Higher Risks
HIV is especially dangerous for infants and young children, even those receiving treatment. Data from 28 countries supported by the U.S. President’s Emergency Plan for AIDS Relief showed that among infants under one year old on antiretroviral therapy, 4.9% died annually. For children aged one to four, the annual death rate was 2.5%. Compare that to 0.7% for adults aged 15 to 49 on the same treatment. Infants on therapy were dying at four to nine times the rate of older age groups.
Young children’s immune systems are less developed, making them more vulnerable to the infections that HIV enables. Without any treatment at all, roughly half of children born with HIV in resource-limited settings historically died before their second birthday, which is why early infant diagnosis and immediate treatment initiation are so critical.
Where You Live Still Determines Survival
The WHO African Region accounts for more than two-thirds of all people living with HIV worldwide, with nearly 1 in every 30 adults carrying the virus. This region also bears a disproportionate share of AIDS deaths, driven by barriers to testing, treatment access, and consistent medication supply. In high-income countries where treatment is widely available, AIDS deaths have become relatively rare. The 630,000 global deaths in 2024 are concentrated overwhelmingly in sub-Saharan Africa and other regions where healthcare systems are strained.
The disease’s deadliness in 2025, in other words, is less about biology and more about geography and resources. The virus itself is no less dangerous than it was in the 1980s. What has changed is that effective treatment exists, and where people can access it consistently, AIDS has become a condition most people survive for decades.
Long-Term Health Risks on Treatment
Living longer with HIV on treatment introduces a different set of health concerns. As people with HIV age, they face elevated rates of cardiovascular disease, liver disease, kidney problems, neurological conditions, and certain cancers that are not directly caused by immune suppression. Cardiovascular disease prevalence in people with HIV is estimated at around 9%, compared to about 5% in the general population. For those co-infected with hepatitis C, the prevalence of advanced liver disease runs between 15% and 30%, compared to 2% to 4% in people with hepatitis C alone.
These conditions, sometimes called non-AIDS-defining diseases, are now a leading cause of death among people with well-controlled HIV. The virus itself and the long-term effects of treatment both appear to contribute to chronic inflammation that accelerates aging-related diseases. This means that while AIDS itself may no longer be the primary threat for someone on effective therapy, HIV still shortens life by increasing vulnerability to the same diseases that affect everyone as they age, just earlier and more frequently.